Search

After 44 days, Kendric Cromer, 12, left the hospital. While his family feels fortunate that he was the first to receive a treatment, their difficult experiences hint at what others [...]

There was supposed to be a special party for Kendric Cromer, 12, last Wednesday, but it had to be postponed because he was too groggy to celebrate. It was meant [...]

M2 PRESSWIRE-August 8, 2024-: Stem Cell Therapy Market to Register 11.2% CAGR by 2031 Amidst Expanding Pipeline of Clinical Trials (C)1994-2024 M2 COMMUNICATIONS RDATE:08082024 Stem Cell Therapy Market Size, Share, [...]

M2 PRESSWIRE-June 20, 2024-: Sickle Cell Disease Pipeline Assessment 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, MOA, ROA and Companies by DelveInsight | Bellicum Pharmaceuticals, Novartis, Novo Nordisk, more [...]

M2 PRESSWIRE-May 7, 2024-: CAR-T Pipeline Outlook, FDA Approvals, Clinical Trials, and Companies 2024 (Updated) (C)1994-2024 M2 COMMUNICATIONS RDATE:06052024 DelveInsight's, 'CAR-T Pipeline Insight 2024' report provides comprehensive insights about 120+ [...]

Byline: Carolyn Y. Johnson In a major advance, the Food and Drug Administration on Friday approved two gene therapies that target sickle cell disease, one of which is the first [...]

M2 PRESSWIRE-January 12, 2024-: Car T Cell Therapy For Multiple Myeloma Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CARsgen Therapeutics, Poseida Therapeutics, Juno [...]

M2 PRESSWIRE-January 10, 2024-: Sickle Cell Disease Pipeline Report: FDA, EMA, and PMDA Approvals, Treatments, Clinical Trials, and Companies by DelveInsight | Bellicum Pharmaceuticals, Novartis, Novo Nordisk, Vertex Pharmaceuticals (C)1994-2024 [...]

M2 PRESSWIRE-January 9, 2024-: Assessment of RNA Interference Pipeline and Clinical Trials in 2023: FDA Approvals, Therapeutics, and Companies by DelveInsight | Moderna Therapeutics, GenSight Biologics, Pfizer, bluebird bio (C)1994-2024 [...]

M2 PRESSWIRE-December 12, 2023-: RNA interference Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Moderna Therapeutics, GenSight Biologics, Pfizer, bluebird bio (C)1994-2023 [...]

M2 PRESSWIRE-September 25, 2023-: Sickle Cell Disease Pipeline, Clinical Trials Assessment, FDA Approvals 2023 (Updated) (C)1994-2023 M2 COMMUNICATIONS RDATE:22092023 DelveInsight's, 'Sickle Cell Disease Pipeline Insights 2023' report provides comprehensive insights [...]

M2 PRESSWIRE-July 14, 2023-: TCR Therapy Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 25+ Companies are working to improve the Treatment of Space | Immatics N.V., Anocca AB, Gritstone, [...]

M2 PRESSWIRE-April 11, 2023-: Sickle Cell Disease Pipeline Drugs Analysis Report 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight (C)1994-2023 M2 COMMUNICATIONS RDATE:10042023 DelveInsight [...]

M2 PRESSWIRE-March 2, 2023-: Gene Therapy Competitive Landscape Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments (C)1994-2023 M2 [...]

M2 PRESSWIRE-March 1, 2023-: Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Insights, 2023 Updates | Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies [...]

M2 PRESSWIRE-February 13, 2023-: Sickle Cell Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments (C)1994-2023 M2 [...]

TAMPA, Fla. -- Using the SRT vector and myelosuppressive preparation therapy, Memorial Sloan Kettering ('MSK') reported encouraging results in Nature Medicine, [Boulad, F., Maggio, A., Wang, X. et al. Lentiviral [...]

A clinical trial of a gene therapy for a rare neurological disease is on hold after a participant in the study developed a bone marrow disorder that can lead to [...]

This week on DocWire, editors spoke with Douglas Sborov, MD, Director of the Multiple Myeloma Program at the Huntsman Cancer Institute, about initiatives to expand eligibility to multiple myeloma (MM) [...]

Byline: Robert Preidt HealthDay Reporter Arguments Over Medicaid Work Requirements Called Off by Supreme Court A request by the Biden administration to call off arguments over a Trump administration plan [...]

Byline: Nick Paul Taylor A bluebird bio investigation has found (https://www.businesswire.com/news/home/20210310005286/en/bluebird-bio-Provides-Updated-Findings-from-Reported-Case-of-Acute-Myeloid-Leukemia-AML-in-LentiGlobin-for-Sickle-Cell-Disease-SCD-Gene-Therapy-Program) a LentiGlobin gene therapy is 'very unlikely' to have caused the acute myeloid leukemia (AML) that affected a recipient [...]

First pivotal study of BCMA-directed CAR T cell therapy in triple-class exposed relapsed and refractory multiple myeloma Biologics License Application (BLA) for ide-cel was accepted by FDA for Priority Review, [...]

Bluebird Bio has paused two clinical trials of LentiGlobin, its gene therapy candidate for sickle cell disease (SCD), after learning that a patient who received treatment more than five years [...]

Gene therapy developer bluebird bio suspended clinical trials using its LentiGlobin product for sickle cell disease due to reported cases of hematologic malignancies among patients who received the treatment. The [...]

Byline: Nick Paul Taylor Bluebird bio has suspended (https://www.businesswire.com/news/home/20210216005442/en/bluebird-bio-Announces-Temporary-Suspension-on-Phase-12-and-Phase-3-Studies-of-LentiGlobin-Gene-Therapy-for-Sickle-Cell-Disease-bb1111) two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). [...]

Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and [...]

CAMBRIDGE, Mass. -- Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, [...]

Byline: Arlene Weintraub Shares of Bluebird Bio fell more than 20% in premarket trading Thursday after the gene therapy developer announced that the FDA is hitting the company with quality-control [...]

Bluebird bio has reported end points were met in a clinical trial involving its candidate ALD cell therapy, branded as Lenti-D. Long-term results from the Phase 2/3 Starbeam study (ALD-102/LTF-304) [...]

Bristol Myers Squibb released new data from two clinical trials of Opdivo plus Yervoy-based combinations in non-small cell lung cancer (NSCLC) and updated results from the KarMMa trial of ide-cel [...]

bluebird bio, Inc. (Nasdaq: BLUE) announced today that updated results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of idecabtagene vicleucel (ide-cel; bb2121), an investigational B-cell [...]

-Virtual oral presentation will include updated efficacy and safety data from pivotal Phase 2 KarMMa study of ide-cel- -Biologics License Application under review with U.S. Food and Drug Administration (FDA)- [...]

Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible. Fallout from the spread of COVID-19 infections led several companies to declare [...]

Bristol-Myers Squibb Company (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced positive top-line results from KarMMa, a pivotal, open-label, single arm, multicenter, Phase 2 study of idecabtagene vicleucel [...]

PRINCETON, N.J: Bristol-Myers Squibb has issued the following news release: Bristol-Myers Squibb Company (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced positive top-line results from KarMMa, a pivotal, [...]

Study met its primary endpoint and key secondary endpoint, demonstrating deep and durable responses in a heavily pre-treated multiple myeloma patient population Safety results are consistent with the data presented [...]

M2 PHARMA-December 7, 2020-Magenta Therapeutics, bluebird bio Team On Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle [...]

CAMBRIDGE, Mass: bluebird bio, Inc. has issued the following press release: bluebird bio, Inc. (Nasdaq: BLUE) today announced updated results from the clinical development program for its investigational Lenti-D gene [...]

Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free [...]